Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis

Zhenzhen Liang, PhD¹, Lianchang Liu, PhD¹, Chaowei Wen, PhD², Heya Jiang, MSci², Tianxia Ye, MSci², Shumei Ma, PhD²,³, and Xiaodong Liu, PhD¹,²,³

Abstract

Purpose: Since protein arginine methyltransferase 5 (PRMT5) is abnormally expressed in various tumors, in this study we aim to assess the association between PRMT5 and clinicopathological and prognostic features.

Methods: Electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library were searched until July 25, 2021. The critical appraisal of the eligible studies was performed using the Newcastle–Ottawa Quality Assessment Scale. Pooled hazard ratios (HR) and pooled odds ratios (OR) were calculated to assess the effect. Engauge Digitizer version 12.1, STATA version 15.1, and R version 4.0.5 were used to obtain and analysis the data.

Results: A total of 32 original studies covering 15,583 patients were included. In our data, it indicated that high level of PRMT5 was significantly correlated with advanced tumor stage (OR = 2.12, 95% CI: 1.22-3.70, \( P = .008; \ I^2 = 80.7\% \)) and positively correlated with poor overall survival (HR = 1.59, 95% CI: 1.46-1.73, \( P < .001; \ I^2 = 50\% \)) and progression-free survival (HR = 1.53, 95% CI: 1.24-1.88, \( P < .001; \ I^2 = 0\% \)). In addition, sub-group analysis showed that high level of PRMT5 was associated with poor overall survival for such 5 kinds of cancers as hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer.

Conclusion: For the first time we found PRMT5 was pan-cancerous as a prognostic biomarker and high level of PRMT5 was associated with poor prognosis for certain cancers.

Keywords
PRMT5, cancers, prognosis, clinicopathology, meta-analysis

Background

As a major public health issue, malignant tumor has become the focus of attention. The latest global cancer data showed that cancer burden rose to 19.3 million new cases and 10.0 million cancer deaths in 2020.⁴ Although various therapeutic procedures appeared to control the development of cancers, the survival rates remained dismal, which might be relevant to the lack of early diagnostic and efficient prognostic biomarkers. That’s the reason why we need to develop novel molecular biomarkers for the prediction of the survival outcome for patients.

Protein arginine methyltransferases (PRMTs) are a family of enzymes that methylate the guanidino group of the arginine...
using S-adenosyl methionine (SAM) as a methyl donor, producing mono- or dimethylated arginine residues and S-adenosyl-L-homocysteine.\(^2\) By altering the stability, localization, or activity of the substrate, PRMTs regulate a variety of intracellular functions that are essential for survival.\(^3\) In addition, PRMTs are involved in cancer development through oncogenic signal transduction, cancer stem cell maintenance, and epithelial-mesenchymal transition (EMT).\(^2\) PRMT5 belongs to the type II PRMT family which is responsible for the generation of monomethylated arginine and enantiomeric dimethylarginine.\(^3\) Studies have shown that PRMT5 could inhibit the transcription of tumor suppressors to provide essential conditions for tumor occurrence,\(^6,7\) such as p53, cell cycle related transcription factor E2F-1, tumor suppressor gene ST7, tumor metastasis suppressor gene NM23, apoptosis related protein CASP4, etc. Moreover, studies have shown that the abnormal expression of PRMT5 is closely related to the occurrence and development of a variety of diseases, and the higher expression of PRMT5 appears in such human malignancies as breast cancer, colon cancer, lung cancer, pancreatic cancer, chronic lymphocytic leukemia, and so on.\(^3\)–\(^10\) Meanwhile, high level of PRMT5 is relevant to survival outcome in cancer patients. For example, based on 118 epithelial ovarian cancer tissues, 20 benign ovarian tumor and 12 normal ovary samples, PRMT5 was reported to be highly expressed in epithelial ovarian cancer, meanwhile the level of PRMT5 was correlated with the proliferation activity and the survival of ovarian cancer patients.\(^11\) For hepatocellular carcinoma, the members of the high-PRMT5 group were more likely to have a worse prognosis comparing with those in the low PRMT5 group (5-year overall survival rates, 53 and 76%, respectively).\(^12\) Vinet, M. reported high-PRMT5 expression was associated with lower probabilities of overall survival but had no influence on distant metastasis-free survival.\(^13\)

However, so far no study has systematically evaluated the clinical and prognostic value of PRMT5 in cancers. In this study, we conducted the systematic analysis to evaluate the clinical and prognostic value of PRMT5 in different malignant tumors, and for the first time we found PRMT5 is pan-cancerous as a prognostic biomarker.

Materials and Methods

This meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria.\(^14\) The protocol of this systematic review was registered on the PROSPERO—International Prospective Register of Systematic Reviews (registration number: CRD42021268881).

Study Strategy

We totally searched 5 electronic databases including PubMed, Web of Science, Scopus, ScienceDirect, and the Cochrane Library. Two independent reviewers (LIANG ZZ and MA SM) searched for literatures from January 1, 2000 to July 25, 2020, with search terms “Neoplasm”, “PRMT5,” and their entry words. Detailed search strategies were shown in Supplementary Table S1. Additionally, the references of relevant literature and Supplementary Materials were also screened manually to identify missing relevant publications.

Select Strategy

All articles were screened according to the inclusion and exclusion criteria by 2 independent reviewers. The inclusion criteria were as follows: (1) original studies; (2) papers published in English and focused on human beings; (3) studies performed to investigate the relationship between PRMT5 and any types of survival outcomes, which included overall survival (OS, period from diagnosis to death due to any reason); progression/disease free survival (PFS/DFS, period from first treatment to identification of cancer progression or death); relapse/recurrence free survival (RFS, period between cure from cancer and identification of cancer progression/recurrence), metastasis-free survival (MFS/DMFS, period from diagnosis cancer to diagnosis a (distant) metastatic event); (4) the levels of PRMT5 were measured through any quantitative analysis, and were divided into 2 levels: high and low; and (5) pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) should be provided, or there should be sufficient data through which HR and 95% CI could be calculated.

The exclusive criteria were as follows: (1) studies without control groups; (2) studies using duplicated data; (3) studies unable to get full-text.

Data Extraction

Two reviewers (LIANG ZZ and MA SM) independently extracted information from each study. Information were shown in detail in Table 1, (1) information of articles, which contains author name, year of publication and region of study; (2) information of patients, which contains age, sex proportion, clinicopathological features, time of follow-up; (3) information of PRMT5, which contain PRMT5 detection methods, number of patients with high/low PRMT5, cut-off; (4) information of survival data, which contain survival outcome indicators (OS, PFS, DFS, and MFS), HRs, and 95% CIs. The quality of the selected studies was independently evaluated by two reviewers using the Newcastle–Ottawa Scale (NOS; star system; range, 0–9 stars), which scored each study based on the methodological items.\(^15\) Studies with a NOS score of 7 or more were thought of methodological high-quality.

Statistical Analysis

We used pooled OR and corresponding 95% CI to estimate the relation of PRMT5 and the clinicopathological features; and used pooled HR and corresponding 95% CI to estimate the relation of PRMT5 and the survival outcomes in cancers.
| First author | Publication year | Country | Ethnicity | Cancer type | Year of patients collection | Patients age | PM/PM' | Tumor stage I + II/III | Lymph node metastasis/Stage/Unknown | Differentiation with moderate/ poor/ unknown | Tumor size | Simple size | Follow-up time | Detection method | High/low expression/sample size | Cut-off | Surviv... | HR status | HR | HRL | HRH |
|-------------|-----------------|---------|-----------|-------------|-----------------------------|-------------|--------|---------------------|---------------------------------|---------------------------------|-----------|-----------|---------------|-------------------|-----------------------------|--------|------------|-----------|----|-----|-----|
| Xiangming Bai | 2013            | China   | Asian     | Epithelial ovarian cancer | 2005.1–2008.12 | 24–86 | 0/118 | 38/50 | 2.24/0.97 | 30/73/15 | NA | 118 | 32 (3–8) | IHC | 98/20 | 4 | OS | SC | 1.66 | 0.6 | 4.57 |
| Xiangming Bai | 2013            | China   | Asian     | Epithelial ovarian cancer | 2005.1–2008.12 | 24–86 | 0/118 | 38/50 | 2.24/0.97 | 30/73/15 | NA | 118 | 32 (3–8) | IHC | 98/20 | 4 | PFS | SC | 1.84 | 0.7 | 5.09 |
| Roen Ishikawa | 2014            | Japan   | Asian     | Lung adenocarcinoma | 2005.6–2008.9 | 34–86 | 75/35 | 100/20.5 | 2.91/01 | NA | ≤3, 38, >3 | 92 | 1.26 | NA | IHC | 47/79 | 5 | (Supplementary Material) | OS | SC | 1.1 | 1.6 | 7.41 |
| Buda Zhang | 2015            | China   | Asian     | Colorectal cancer | 2011–2012 | 24–90 | 47/40 | 56/34 | NA | ≤4, 30 | >4, 60 | 90 | NA | IHC | 56/34 | 4 | OS | SC | 1.99 | 0.9 | 4.15 |
| Buda Zhang | 2015            | China   | Asian     | Hepatocellular carcinoma | NA | 38–72 | 48/6 | 49/11 | NA | ≤5, 27 | >5 | 27 | 54 | NA | IHC | 31/23 | 4 | OS | Rep | 2.411 | 1.094 | 5.313 |
| Feng Yue  | 2015            | USA     | Caucasian | Glioblastoma | 2003.2–2007.10 | 32–71 | 24/19 | NA | NA | NA | 40 | NA | IHC | 1528 | 3 | (Supplementary Material) | OS | Rep | 1.4 | 1.18 | 1.66 |
| Mitsuo Kanda | 2016            | Japan   | Asian     | Gastric cancer | 2001–2010 | <65, 79 | ≥65, 180 | 137/42 | 61/10 | 2.71/52 | 71/108 | ≤5, 74 | ≥5 | 105 | 179 | NA | POC array | 90/89 | Median expression | OS | Rep | 3.9 | 1.59 | 10.2 |
| Delia Yang | 2016            | China   | Asian     | Nasopharyngeal carcinoma | 2018.12–2010.2 | <50, 37 | >50, 35 | 77/35 | 54/38 | 9/103 | NA | NA | 112 | NA | Immunohistochemistry | 49/72 | 4 | OS | SC | 6.39 | 3.08 | 13.32 |
| Bina Kumari | 2017            | USA     | Caucasian | Oropharyngeal squamous cell carcinoma | 2002–2009 | NA | 166/15 | 16/19 | NA | NA | 209 | NA | IHC | 58/151 | Nuclear expression | OS | Rep | 1.73 | 1.13 | 2.66 |
| Da Shengzhao | 2017            | Japan   | Asian     | Hepatocellular carcinoma | 1998.1–2012.1 | 34–84 | 121/23 | 127/17 | NA | 35/109 | ≤5, 46 | ≥5, 98 | 144 | NA | qRT-PCR | 72/72 | Median level | OS | SC | 1.91 | 1.1 | 3.38 |
| Madhurima Ranganay | 2017 | USA     | Caucasian | Breast cancer | METABRIC data | NA | NA | NA | NA | NA | 1714 | NA | RNA-seq, microarray | 192/1322 | 90% | qRT-PCR | 2.14 | 1.81 | 2.53 |
| Ying Yang | 2017            | China   | Asian     | Breast cancer | GEO database | NA | NA | NA | NA | NA | 1660 | NA | RNA-seq, microarray | 4621/1178 | Median expression | OS | Rep | 1.73 | 1.47 | 2.05 |
| Ying Wu  | 2017            | China   | Asian     | HER-2 positive breast cancer | GEO database | NA | NA | NA | NA | NA | 66 | NA | RNA-seq, microarray | 40/26 | Median expression | OS | Rep | 0.39 | 0.16 | 1.1 |
| Ying Wu | 2017            | China   | Asian     | Triple negative breast cancer | GEO database | NA | NA | NA | NA | NA | 132 | NA | RNA-seq, microarray | 63/99 | Median expression | OS | Rep | 2.53 | 1.15 | 5.56 |
| Arvindra jain | 2017 | USA     | Caucasian | Maliglute | NA | NA | NA | NA | NA | NA | 320 | NA | qRT-PCR | 80/240 | Top 25% | OS | SC | 1.69 | 0.63 | 4.52 |
| Arvindra jain | 2017 | USA     | Caucasian | Malignant Melanoma | NA | NA | NA | NA | NA | NA | 320 | NA | qRT-PCR | 80/240 | Top 25% | PFS | SC | 1.55 | 1.07 | 2.25 |
| Xin Zhao | 2018            | China   | Asian     | Gastric cancer | 2001.1–2010.12 | ≥60, 284 | <60, 318 | 400 | 202 | 58/014 | 54/46 | 40/207/552 | NA | 402 | NA | IHC | 43/169 | 3 | OS | SC | 1.22 | 0.9 | 1.51 |
| Pingjia Jie  | 2018            | China   | Asian     | Lung cancer | 2004–2013 | ≥60, 89 | >60, 1189 | 124/85 | 1.15/94 | NA | 209 | NA | IHC | 88/123 | NA | OS | SC | 1.53 | 0.99 | 2.16 |
| He Jie  | 2018            | China   | Asian     | Hepatocellular carcinoma | 2005–2012 | ≥52, 74 | >52, 64 | 117/21 | 76/4 | NA | 38/101 | ≤5, 53 | ≥5, 80 | 138 | NA | IHC | 117/21 | 5 | OS | Rep | 1.893 | 1.113 | 3.219 |
| Zhifeng Liu | 2018            | China   | Asian     | Hepatocellular carcinoma | 1999–2006 | 26–78 | 175/20 | 154/119 | NA | NA | 195 | 60 months (0–142) | 106/89 | 3 | OS | Rep | 1.712 | 1.176 | 2.492 |
| Mathilde Vest | 2019 | France | Caucasian | Breast cancer | NA | NA | NA | NA | NA | NA | 153 | NA | Microarray | 76/77 | Median expression | OS | SC | 1.61 | 0.77 | 3.35 |
| Mathilde Vest | 2019 | France | Caucasian | Breast cancer | NA | NA | NA | NA | NA | NA | 145 | NA | Microarray | 73/72 | Distant metastases (lung, bone, liver) | OS | SC | 1.87 | 0.79 | 4.01 |
| Yi Qin | 2019            | China   | Asian     | Pancreatic cancer | NA | <60, 22 | ≥60, 33 | 32/23 | NA | 2.055 | 10/31/14 | ≤4, 34 | ≥4 | 23 | 55 | NA | IHC | 37/18 | 2 | OS | SC | 1.21 | 0.56 | 2.62 |

(continued)
| First author                  | Publication year | Country    | Ethnicity | Cancer type                  | Year of patients collection | Patients age | Tumor stage I + II/unknown | Lymphatic metastasis Yes/unknown | Tumor size | Simple size | Follow-up time | Detection method | High-low expression sample size | Cut-off | Survival analysis indicators | HR statistic | HRH | HR | HRL |
|------------------------------|------------------|------------|-----------|--------------------------------|-----------------------------|--------------|--------------------------|-------------------------------|------------|-------------|----------------|----------------|-------------------------------|---------|---------------------|--------------|------|-----|------|
| Yi Qu                      | 2019             | China      | Asian     | Pancreatic cancer              | NA                          | 56–75        | 80–97                    | 24:13                         | 177        | NA          | NA             | RNA-seq                      | 89/188                      | NA      | OS                  | 1.77          | 1.12 | 2.57 |
| Lu Ge                      | 2020             | Germany    | Caucasian | Chronic lymphocytic leukemia   | NA                          | 56–75        | 80–97                    | 24/13                         | 177        | NA          | NA             | RNA-seq                      | 89/188                      | NA      | OS                  | 1.62          | 1.11 | 2.36 |
| Lei Tan                    | 2020             | China      | Asian     | Bladder cancer                 | 2002–2016                   | NA           | 65                        | 13/19                         | 92         | NA          | NA             | qRT-PCR                     | 82/50                       | NA      | OS                  | 2.03          | 1.21 | 3.87 |
| Yu-Hang Li                 | 2020             | China      | Asian     | Osteosarcoma                   | R2 Genomics Analysis and Visualization Platform | NA           | 65                        | 13/19                         | 92         | NA          | NA             | RNA-seq                      | 89/188                      | NA      | OS                  | 1.85          | 1.07 | 2.67 |
| Nan Wang                   | 2020             | China      | Asian     | Laryngeal carcinoma            | 2010.1–2018.12              | NA           | >58, 42                   | 55/33                         | 499        | 88          | NA             | qPCR                       | 44/44                       | NA      | OS                  | 2.14          | 1.20 | 3.56 |
| Xiao Han                   | 2020             | China      | Asian     | Breast cancer                  | 2014.7–2016.3               | NA           | >51, 41                   | 47/3                         | 291/6      | 80          | NA             | RT-PCR                     | 45/35                       | NA      | OS                  | 1.45          | 1.11 | 1.9  |
| Dong Wang                  | 2020             | China      | Asian     | Gastric cancer                 | NA                          | >60, 52       | NA                       | NA                           | 335/335    | 166/169      | NA             | RNA-seq                      | 313/173                      | NA      | OS                  | 1.45          | 1.15 | 1.82 |
| Ming Lu                    | 2020             | China      | Asian     | Uterine cervical cancer        | NSA                         | 60–75        | 62/8                      | 197/23                       | 90         | NA          | NA             | PCR                       | 45/45                       | NA      | OS                  | 2.07          | 1.32 | 3.50 |
| Wajid Ahmad Bhati           | 2021             | United Arab Emirates | Asian | Lung adenocarcinoma           | 2008–2013.7                 | NA           | >65, 50                   | 58/46                         | 71/9       | 43/59        | NA             | RNA-seq                      | 32/32                       | NA      | OS                  | 1.78          | 1.23 | 2.58 |
| Liu Lili                   | 2021             | China      | Asian     | Lung adenocarcinoma            | 2008–2013.7                 | NA           | >65, 50                   | 58/46                         | 71/9       | 43/59        | NA             | RNA-seq                      | 32/32                       | NA      | OS                  | 1.78          | 1.23 | 2.58 |
### Table 1. (continued)

| First author | Publication year | Country | Ethnicity | Cancer type      | Year of patients collection | Patients age | Male/ female | Tumor stage I + IV / unknown | Lymphadenectomy metastasis / unknown | Differentiation Well-/moderate-poor/unknown | Tumor size | Sample size | Follow-up time | Detection method | High/low expression sample size | Cut-off | Survival analysis indicators | HR status | HR | HRl | HRH |
|--------------|------------------|---------|-----------|------------------|-----------------------------|-------------|--------------|-----------------------------|-----------------------------------|-------------------------------------|------------|--------------|----------------|--------------------------|-----------------------------|---------|----------------------|---------|-----|-----|-----|
| Liu et al.   | 2021             | China   | Asian     | Lung adenocarcinoma | 2008.2–2013.7               | >60, 50 ≤ 60, 31               | 56/46 | 71/31 | 43/59 | NA | NA | 102 | NA | IHC | 48/54 | 3 | OS, SC | 1.44 | 1.14 | 1.81 |
| Jie Gao      | 2021             | China   | Asian     | Cervical cancer    | Oncomine                   | NA | NA | NA | NA | NA | NA | NA | NA | NA | RNA-seq/microArray | 170/134 | NA | OS | Rep | 2 | 1.21 | 3.32 |
| Jie Gao      | 2021             | China   | Asian     | Breast cancer      | Oncomine                   | NA | NA | NA | NA | NA | NA | NA | NA | NA | RNA-seq/microArray | 546/1218 | NA | OS | Rep | 1.67 | 1.42 | 1.95 |
| Jie Gao      | 2021             | China   | Asian     | Lung cancer        | Oncomine                   | NA | NA | NA | NA | NA | NA | NA | NA | NA | RNA-seq/microArray | 537/1389 | NA | OS | Rep | 1.35 | 1.34 | 1.75 |
| Jie Gao      | 2021             | China   | Asian     | Liver cancer       | Oncomine                   | NA | NA | NA | NA | NA | NA | NA | NA | NA | RNA-seq/microArray | 200/164 | NA | OS | Rep | 1.59 | 1.11 | 2.26 |
| Jie Gao      | 2021             | China   | Asian     | Gastric cancer     | Oncomine                   | NA | NA | NA | NA | NA | NA | NA | NA | NA | RNA-seq/microArray | 335/306 | NA | OS | Rep | 1.28 | 1.05 | 1.57 |
| Xiangwei Li  | 2021             | China   | Asian     | Colorectal cancer  | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | IHC | 50/49 | NA | OS | SC | 1.82 | 1.01 | 3.29 |

NA: not available; IHC: Immunohistochemistry; OS: overall survival; PFS: progression-free survival; DFS: disease free survival; RFS: relapse free survival; MFS: metastasis-free survival; DMFS: distant metastasis-free survival; Rep: reported; SC: survival curve; HR: hazard ratio; HRL: HR; HRL: Lower limit of 95% confidence interval; HRH: HRH: Upper limit of 95% confidence interval; cut-off means the threshold for distinguishing high/low expression of PRMT5.
We extracted HRs on the basis of the methods reported in several articles. If HRs were reported in the studies, we extracted the HRs directly. If both of the data from univariate analysis and multivariate analysis could be extracted, we chose multivariate analysis to improve data accuracy. If there was no direct information about HRs, then we retrieved HRs by extracting some survival rates at specified times from Kaplan-Meier Curves using Engauge Digitizer version 12.1. When pooled HR>1, we could reach the conclusion that the aberrant level of PRMT5 was associated with poor prognosis.

As included studies showed differences in some characteristics, we used the random-effects model to calculate pooled effect sizes. Publication bias was assessed by Begg’s funnel plots asymmetry test and Egger’s test, if the Begg’s Funnel plot graphics were symmetrical and $P > .05$, it suggested no significant publication bias. Forest plots were used to display the results and sensitivity analyses were also performed to assess the effect of each study. Heterogeneity was evaluated by $P$-value of Cochran-$Q$ test and $I^2$-square statistic. If $P$-value $> .05$ and $I^2 < 50\%$, studies were thought to be free of significant heterogeneity; if $P$-value $< .05$ and $I^2 > 50\%$, studies were thought to be of heterogeneity, and sub-groups analyses were performed to seek covariates that contributed to heterogeneity. Statistically significance was considered whenever $P$-values $< .05$. Engauge Digitizer version 12.1, STATA version 15.1 and R version 4.0.5 were used to obtain the data and analysis above.

**Results**

**Study Selection**

According to the search strategy, 3816 articles were found, including 387 from PubMed, 436 from Web of Science, 2017 from Scopus, 973 from ScienceDirect, and 3 from Cochrane Library. After elimination of 1159 duplications, 2657 were left. 2492 of them were removed after title and abstract scan according to inclusion and exclusion criteria. 165 of them were eliminated after full-text scan according to inclusion and exclusion criteria. 122 articles were eliminated for insufficient data. 35 articles were eligible. 32 studies were included in qualitative synthesis (meta analysis).
exclusion criteria. 122 articles were eliminated for insufficient data. Among the left 35 articles, 3 articles could not be used to extract HRs and 95% CIs from the survival curves. Finally, 32 articles were included, those articles were published between January 1, 2013 and July 25, 2021. The flow diagram was shown in Figure 1.

**Study Characteristic**

A total of 50 studies were included in the 32 articles. Among them, 13 articles provided relatively complete clinicopathological data, which was enough to obtain a pooled OR to assess the relationship between PRMT5 and tumor stage, lymphatic metastasis and degree of differentiation.

The survival indicators involved in the 50 studies included OS, PFS, DFS and DMFS (42 studies were OS, 3 studies were PFS, 2 studies were DFS, 1 study was MFS, and 1 study was DMFS). Of all the 50 studies, for the detection of PRMT5 16 studies used immunohistochemistry (IHC), 17 studies used PCR technology (RT-PCR, qPCR, and microarray), 11 studies used The Cancer Genome Atlas (TCGA) data which took RNA-Seq as PRMT5 detection method, 1 study used METABRIC data, 2 studies used caBIG, TCGA, and Gene Expression Omnibus (GEO) database simultaneously, and 3 studies used 26 datasets from GEO. The sample size of each study is between 43 and 1926. Among the 50 studies, 7 studies were about breast cancer, 7 studies were about lung cancer, 5 studies were about hepatocellular carcinoma, 5 studies were about pancreatic cancer, 4 studies were about gastric cancer, and so on. As for the study location, excluding studies based on TCGA, GEO, METABRIC data, caBIG data, or ICGC CLLE project, the remaining 30 studies include 20 from China, 3 from Japan, 5 from the United States, and 2 from France. Detailed information was shown in Table1 and Supplementary Table S2.

**Assessment of Methodological Quality**

The ranking of each study is shown in Supplementary Table S3. The NOS scores in the column titled “Comparability of Cohorts on the Basis of the Design or Analysis” indicate that some of the studies provided details regarding their design. In the studies by M Rengasamy, Y Wu, Lu Ge, YH Li, AK Schnormeier, G Walbrecq, W Barczak, Bajbouj K, and Gao J, authors used RNA-Seq data from public database, such as TCGA, GEO, METABRIC data, but the authors did not provide study design of the included patients as well as the follow-up time, hence, a star could not be awarded. According to the assessment results, the studies included in this meta-analysis were considered high-quality studies.
Publication Bias and Heterogeneity

In this study, only when the number of studies on survival indicators is greater than or equal to 3, we conduct a meta-analysis. Thus, we only conducted on OS and PFS.

Publication bias was evaluated by Begg’s Funnel plot and the Egger’s test when the number of studies included was over 10. However, the number of studies on PFS was less than 10, which was not suitable for publication bias testing. Therefore, we only tested the OS publication bias. Begg’s Funnel plot graphics were symmetrical and \( P > .05 \), which suggested no significant publication bias. (Figure 2)

For heterogeneity, there was moderate heterogeneity in OS group for \( I^2 = 50.0\% \) and \( P < .001 \), and no significant heterogeneity was found in the group of PFS for \( I^2 = 0\% \) and \( P = .926 \).

PRMT5 and Clinicopathological Parameters

Among the 32 articles, 11 articles investigated the associations between PRMT5 and tumor stage. There were 832 cases with high level of PRMT5 and 664 cases with low level of PRMT5. Of all the 832 PRMT5-overexpressed patients, 434 patients were of III-IV stage and 241 patients were of III-IV stage among 664 PRMT5 low expressed patients (Supplementary Table S2). The pooled results showed that

![Figure 4. Meta-analysis results for the overall survival of sub-groups. A: detection method; B: ethnicity; and C: different cancer type.](image)

**Table 2. The Prognostic Effects of Sub-Groups About Overexpression of PRMT5 and OS for Cancer Patients.**

| Subgroup analysis        | No. of studies | No. of patients | Pooled HRs (95% CI) | Z value | P-value | Heterogeneity | Z value | P-value |
|--------------------------|----------------|----------------|---------------------|---------|---------|---------------|---------|---------|
| Ethnicity                |                |                |                     |         |         |               |         |         |
| Asian                    | 20             | 2790           | 1.73 (1.49, 2.00)   | 7.29    | <.001   | 39.6          | .036    |         |
| Caucasian                | 5              | 818            | 1.59 (1.27, 1.97)   | 4.13    | <.001   | 18.0          | .300    |         |
| PRMT5 level              |                |                |                     |         |         |               |         |         |
| RNA                      | 27             | 11238          | 1.60 (1.42, 1.80)   | 7.69    | <.001   | 61.9          | <.001   |         |
| Protein                  | 15             | 2133           | 1.49 (1.36, 1.63)   | 8.46    | <.001   | 0             | .508    |         |
| Cancer type              |                |                |                     |         |         |               |         |         |
| BC                        | 6              | 3909           | 1.63 (1.22, 2.19)   | 3.28    | .001    | 70.4          | .005    |         |
| GC                        | 4              | 1512           | 1.32 (1.04, 1.69)   | 2.26    | .024    | 48.9          | .118    |         |
| HCC                      | 5              | 895            | 1.75 (1.42, 2.17)   | 5.19    | <.001   | 0             | .899    |         |
| PC                        | 4              | 480            | 1.57 (1.24, 1.98)   | 3.78    | <.001   | 0             | .752    |         |
| LC                        | 7              | 3661           | 1.35 (1.22, 1.50)   | 5.95    | <.001   | 0             | .982    |         |

BC: breast cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; LC: lung cancer; PC: pancreatic cancer.
PRMT5 has no significant correlation with positive lymph node metastasis and tumor differentiation (OR = 1.58, 95% CI: 0.97-2.59, P = .069; OR = 0.72, 95% CI: 0.39-1.33, P = .297). (shown in Figure 3B and C)

**Overall Survival Analysis**

There were 42 studies, comprising a total of 13371 patients, provided data for us to analyze the correlation between PRMT5 and OS. As shown in Figure 3D, the data indicated that the high level of PRMT5 had an obvious impact on OS (HR = 1.59, 95% CI: 1.46-1.73). And the pooled estimated HR for all studies showed a significant difference (z = 10.57, P < .001). The overall results suggested that high-PRMT5 expression is an indicator of poor OS in patients with cancer.

**Progression-Free Survival Analysis**

HRs for PFS were available in 3 studies for a total of 845 patients. As shown in Figure 3E, the data indicated that the
high expression of PRMT5 had an obvious impact on PFS (HR = 1.53, 95% CI: 1.24–1.88). And the pooled estimated HR for all studies showed a significant difference (z = 4.02, P < .001). The overall results suggested that high-PRMT5 expression was an indicator of poor PFS in patients with cancer.

Sub-group Analysis for Overall Survival

Because of heterogeneity in samples for calculating pooled OS (I² = 50.0% and P < .001), sub-group analyses were performed for PRMT5 detection method, ethnicity and different cancer type. As mentioned previously, qPCR, RT-PCR, microarray, RNA-Seq, and IHC were used to detect PRMT5. It can be seen that the detection of PRMT5 is mainly from the RNA level (qPCR, RT-PCR, microarray, and RNA-Seq) and the protein level (IHC). Therefore, we classify the detection of PRMT5 into 2 categories: RNA level and protein level. Of all the 42 studies, 27 studies were from RNA level and 15 studies were from protein level. Regardless of RNA level or protein level, high expression of PRMT5 was associated with a poor OS, for HR = 1.60, 95% CI: 1.42–1.80 (RNA level) and HR = 1.49, 95% CI: 1.36–1.63 (protein level), respectively. Meanwhile, we found that I² for RNA level was 61.9% while I² for protein level was 0%, suggesting that different PRMT5 detection methods might be one of the sources of heterogeneity, and the stability of the detection result of PRMT5 protein level was better than that of RNA level. As for ethnicity, considering that the PRMT5 expression data obtained from the public databases (TCGA, GEO, METABRIC, Oncomine, and caBIG) contains different ethnicity, and the ethnic information of the included population was not clarified in the original article, in the sub-group analysis based on ethnicity, we excluded the studies based on public databases. Among the remaining 25 studies, 20 were for Asian populations and 5 were for Caucasians. The results showed that whether Asian populations or Caucasian, high expression of PRMT5 was associated with poor prognosis (HR = 1.73, 95% CI:1.49–2.00; HR = 1.59, 95% CI:1.27–1.97). It also showed that the heterogeneity between studies from Asians was higher than that from Caucasians for I² = 39.6, P = .036 and I² = 18.0, P = .300, respectively. In addition, we also conducted a sub-group analysis based on different cancer types. We analyzed tumors with more than 3 studies and the results showed that high expression was associated with poor prognosis for all of the following 5 kinds of cancers: hepatocellular carcinoma, pancreatic cancer, breast cancer, gastric cancer, and lung cancer, suggesting that PRMT5 is pan-cancerous as a prognostic biomarker. In addition, the heterogeneity among studies about breast cancer is high (I² = 70.4, P = .005), which might be caused by complex subtyping of breast cancer; the heterogeneity among studies about gastric cancer is moderate (I² = 48.9, P = .118); and there was no heterogeneity for hepatocellular carcinoma, pancreatic cancer and lung cancer (I² = 0). Therefore, different cancer type was also the source of heterogeneity for OS (Table 2 and Figure 4).

Sensitivity Analysis

Sensitivity analysis was performed to assess the influence of sequential omission of each individual study on the overall survival. The results suggested that there was no significant influence of the pooled HR by removing any study, indicating our analysis was robust (shown in Figure 5).

Discussion

Why Is PRMT5 Chosen?

PRMT5 is an enzyme which is acquiring increased prominence in cancer.44 It is the major symmetric arginine methyltransferase in mammalian cells, and has been reported to be a novel therapeutic target molecule for human tumors.45 PRMT5 could be regulated the expression of a wide spectrum of cellular events, including cell growth/proliferation, tie 2 cell invasion/migration, epithelial-mesenchymal transition,46 alternative splicing,47 altering DNA replication and genomic instability48 and dysregulation of cell cycle progression.49 PRMT5 was considered to be involved in the occurrence and development of tumors, and high level of PRMT5 was thought to be associated with aggressive clinicopathological parameters, such as poor differentiation, higher incidence of vein invasion and larger tumor size.50 Thus, as an oncoprotein, PRMT5 has gained increasing attention in terms of cancer prevention and therapy in recent years. Meanwhile, PRMT5 is under investigation as a potential therapeutic target for cancer in clinical practice.5 In addition, we also found that the level of PRMT5 in whole blood is related to the prognosis of liver cancer in our multi-center study of liver cancer cases. Considering the important role of PRMT5, we searched for studies on PRMT5 and found that there are many literatures reporting the relationship between PRMT5 and clinical features or patient survival outcomes, then we did this systematic review and meta-analysis to clarify the relationship between the level of PRMT5 and the clinicopathological features and prognostic value of patients with tumors comprehensively and systematically.

What Did We Find and the Significance of the Phenomena

In this study, we included 32 articles with a total of 15583 patients to clarify the relationship between PRMT5 and tumor prognosis. We confirmed that (1) there were remarkable positive associations between PRMT5 and advanced clinical tumor stage; (2) high level of PRMT5 was related to poor OS and PFS, and increased the risk of death in cancer patients. These results indicated that PRMT5 might serve as a clinicopathological and prognostic biomarker for malignancy. Furthermore, by sub-group analysis, we found that in breast cancer, the relationship between PRMT5 and tumor prognosis is quite heterogeneous and it has good consistency in the prognosis of liver cancer, pancreatic cancer and lung cancer.
Through tracing the original researches, the main reason, to some extent, attributes to sub-types of breast cancer. Some of the included literatures are for triple negative breast cancer, some are HER-2 positive breast cancer, and some do not specifically list the sub-types; in addition, PRMT5 expression based on protein level detection, compared with RNA level, has a more consistent effect on the prognosis of cancer patients, which might be derived from the reason that the detection of RNA are diverse (RNA-Seq, qPCR, RT-PCR, and microarray) and the detection results have a wide distribution range, while protein detection has only one method of IHC, and the score distribution range is narrow. All in all, these results indicated that PRMT5 might serve as a clinicopathological and prognostic biomarker for malignancy, but the detection method of PRMT5 and tumor types, especially breast cancer subtyping, have a great impact on the relationship between PRMT5 and OS.

As above-mentioned, tumors are still a major global public health problem. With the development and the advance of medicine, cancer treatment methods have become more diverse, but the incidence and mortality of malignant tumors have not been well controlled. From 10 million new cases, 6 million deaths, and 22 million people living with cancer in 2000 to an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020, cancer is still the main killer threatening the lives and health of all human beings. The proposal of precision medicine makes clinicians pay more attention to individualized prevention, treatment and disease monitoring. This requires more biomarkers to feed back the patient’s condition in a timely and effective manner, and to change prevention or treatment measures as soon as possible. In our study, by summarizing the data of various original studies, we have clarified that the high level of PRMT5 is related to tumor stage, poor OS and PFS. This provides a basis for tumor monitoring.

Possible Mechanism of PRMT5 as a Tumor Biomarker

There is evidence indicating that PRMT5 can silence tumor suppressor genes and act as an oncogene, accelerating tumor growth and metastasis. This may explain why PRMT5 can act as a biomarker for advanced stage tumors and lymphatic metastasis. Mechanistically, PRMT5 is a pleiotropic enzyme involved in diverse processes. (1) It is an established regulator of RNA biogenesis, in particular RNA splicing, which frequently becomes aberrant in cancer. For example, PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes; PRMT5 deficiency mainly interferes with the deletion of introns. This impaired splicing affects proliferation genes, meanwhile, its down-regulation is consistent with cell cycle defects and apoptosis. (2) PRMT5 performs its function mainly through epigenetic silencing or direct methylation of histone and non-histone molecules, thereby regulating cellular processes, including transcription, proliferation, apoptosis and metabolism. For example, PRMT5 regulates cell invasion by inducing transcriptional activation and inhibition through methylation of histones H3 and H4; PRMT5 enhances the methylation of PDCD4, thereby promoting tumor cell viability, allowing the tumor to grow more aggressively; Inhibition of PRMT5 changes the methylation status of E2F-1, leading to attenuated DNA damage repair, cell cycle arrest, and increased apoptosis flux. In addition, as a co-factor in a DNA damage responsive co-activator complex that interacts with p53, PRMT5 is responsible for methylating p53. PRMT5 depletion triggers p53-dependent apoptosis.

Above all, PRMT5 is related to cell death, overexpression of PRMT5 enhances the cell proliferation and weakens the ability of apoptosis, and high level of PRMT5 is associated with poor prognosis, which makes PRMT5 a potential prognostic biomarker.

Limitations

There are several limitations in this study that should be acknowledged. Firstly, the articles included in the meta-analysis were from only 5 available databases (PubMed, Web of Science, Scopus, ScienceDirect, and Cochrane Library) and limited to written in English, thus, the data collection might be incomplete. Although we tried to include all published literatures, and there was no significant publication bias, most of the articles included were from Asian, which might attribute to the decreased generality and heterogeneity; Secondly, different criteria were applied in these studies for defining PRMT5 high or low level, because of the lack of uniform cut-off values in PRMT5 detection. This makes it impossible for us to give a clear threshold for distinguishing high level of PRMT5 in our study; Thirdly, HRs with 95% CIs were calculated by digitizing and extracting from the survival curves in most of the including papers, which inevitably brought minor statistical deviations. Furthermore, the effects of some factors, such as treatment strategy and family history, were not considered in this analysis due to the insufficient data. Therefore, high-quality studies are urgently needed to draw more accurate conclusions.

Our meta-analysis provided credible evidence that high level of PRMT5 was significantly related to advanced tumor stage and the poor prognosis for cancer patients. In addition, given the important prognostic factor of survival for cancer patients, PRMT5 might serve as an attractive therapeutic target in the treatment of malignant tumors.

Conclusion

For the first time we found PRMT5 was pan-cancerous as a prognostic biomarker, and high level of PRMT5 was associated with poor prognosis for certain cancers.
Appendix

Abbreviations

- PRMT5: protein arginine methyltransferase 5
- HR: hazard ratios
- OR: odds ratios
- 95% CI: 95% confidence interval
- PRISMA: the Preferred Reporting Items for Systematic Reviews and Meta-analysis
- OS: overall survival
- PFS/DFS: progression/disease free survival
- RFS: relapse/recurrence free survival
- MFS/DMFS: metastasis-free survival
- IHC: immunohistochemistry
- TCGA: The Cancer Genome Atlas
- GEO: Gene Expression Omnibus

Author Contributions

Liang Z was in charge of the writing of manuscript. Liu L and Wen C were in charge of editing the manuscript. Jiang H and Ye T were in charge of data analysis. Ma S was in charge of the revision of manuscript. Liu X conceived and designed this study, reviewed the manuscript and was responsible for the overall content as guarantor.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Natural Science Foundation of China (81972969, 81872558, 81773363, and 81673092). The funding body had no role in the design of the study, collection, analysis, and interpretation of the data, or preparation of the manuscript.

Ethical approval

This article does not contain any studies with human or animal subjects performed by the any of the authors.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

ORCID iD

Xiaodong Liu https://orcid.org/0000-0002-6879-990X

Supplemental Material

Supplemental material for this article is available online.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
2. Iyamu ID, Al-Hamashi AA, Huang R. A pan-inhibitor for protein arginine methyltransferase family enzymes. Biochemistry. 2021;11:854.
3. van Lieshout TL, Ljubicic V. The emergence of protein arginine methyltransferases in skeletal muscle and metabolic disease. Am J Physiol Endocrinol Metab. 2019;317:E1070-e1080.
4. Jarrod J, Davies CC. PRMTs and arginine methylation: Cancer’s best-kept secret?. Trends Mol Med. 2019;25:993-1009.
5. Liu M, Yao B, Gui T, et al. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 2020;10:4437-4452.
6. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004;24:9630-9645.
7. Zhu F, Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes Dis. 2019;6:247-257.
8. Han X, Wei L, Wu B. PRMT5 promotes aerobic glycolysis and invasion of breast cancer cells by regulating the LXRalpha/NF-kappaB pathway. Onco Targets Ther. 2020;13:3347-3357.
9. Ibrahim R, Matsubara D, Osman W, et al. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Hum Pathol. 2014;45:1397-1405.
10. Barczak W, Jin L, Carr SM, et al. PRMT5 promotes cancer cell migration and invasion through the E2F pathway. Cell Death Dis. 2020;11:572.
11. Bao X, Zhao S, Liu T, Liu Y, Liu Y, Yang X. Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer. J Histochem Cytochem. 2013;61:206-217.
12. Shimizu D, Kanda M, Sugimoto H, et al. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy. Int J Oncol. 2017;50:381-386.
13. Vinet M, Suresh S, Maire V, et al. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers. Cancer Med. 2019;8:2414-2428.
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Group preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
15. Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. In: Symposium on Systematic Reviews: Beyond the Basics; 2014
16. Chen G, Wang J, Chen K, et al. Relationship between post-operative complications and the prognosis of gastric carcinoma patients who underwent surgical resection: a systematic review and meta-analysis. Cancer Control. 2021;28:10732748211011955.
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:1-16.
18. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 2004;23:2815-2834.
19. Fan Z, He L, Li M, et al. Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription. Neoplasia. 2020;22:617-629.
20. Ge L, Wang H, Xu X, et al. PRMT5 promotes epithelial-mesenchymal transition via EGFR-beta-catenin axis in pancreatic cancer cells. J Cell Mol Med. 2020;24:1969-1979.
21. Gulla A, Hideshima T, Bianchi G, et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2018;32:996-1002.
22. Jiang H, Zhu Y, Zhou Z, et al. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma. Cancer Med. 2018;7:869-882.
23. Jing P, Zhao N, Ye M, et al. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling. Cancer Lett. 2018;427:38-48.
24. Kanda M, Shimizu D, Fujii T, et al. Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. Int J Oncol. 2016;49:1195-1202.
25. Lin Z, Jia H, Hong L, et al. Prognostic impact of SET domain-containing protein 8 and protein arginine methyltransferase 5 in patients with hepatocellular carcinoma following curative resection. Oncol Lett. 2018;16:3665-3673.
26. Liu X, Zhang J, Liu L, et al. Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2835-2844.
27. Rengasamy M, Zhang F, Vashisht A, et al. The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer. Nucleic Acids Res. 2017;45:11106-11120.
28. Schnormeier A-K, Pommerenke C, Kaufmann M, Drexlner HG, Koeppel M. Genomic deregulation of PRMT5 supports growth and stress tolerance in chronic lymphocytic leukemia. Sci Rep. 2020;10:1. 
29. Wallbrech G, Lecha O, Gaigneaux A, et al. Hypoxia-induced adaptations of miornomes and proteomes in melanoma cells and their secreted extracellular vesicles. Cancers (Basel). 2020;12.
30. Wang N, Yan H, Wu D, et al. PRMT5/Wnt4 axis promotes lymph-node metastasis and proliferation of laryngeal carcinoma. Cell Death Dis. 2020;11:864.
31. Wu Y, Wang Z, Zhang J, Ling R. Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer. Tumour Biol. 2017;39:1010428317695917.
32. Yan F, Alinari L, Lustberg ME, et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res. 2014;74:1752-1765.
33. Yang D, Liang T, Gu Y, et al. Protein N-arginine methyltransferase 5 promotes the tumor progression and radioresistance of nasopharyngeal carcinoma. Oncol Rep. 2016;35:1703-1710.
34. Zhang B, Dong S, Zhu R, et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015;6:22799-22811.
35. Zhang B, Dong S, Li Z, et al. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin. J Transl Med. 2015;13:349.
36. Kumar B, Yadav A, Brown NV, et al. Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget. 2017;8:14847-14859.
37. Li YH, Tong KL, Lu JL, et al. PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis. Aging (Albany NY). 2020;12:2507-2529.
38. Tan L, Xiao K, Ye Y, et al. High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer. Aging (Albany NY). 2020;12:8728-8741.
39. Qin Y, Hu Q, Xu J, et al. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Commun Signal. 2019;17:30.
40. Bajbouj K, Ramakrishnan RK, Saber-Ayad M, et al. PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung cancer cells. Int J Mol Sci. 2021;22:6131.
41. Liu L, Yan H, Ruan M, et al. An AKT/PRMT5/SREBP1 axis in lung adenocarcinoma regulates de novo lipogenesis and tumor growth. Cancer Sci. 2021;112:3083-3098.
42. Gao J, Liu R, Feng D, et al. Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition. Cell Death Differ. 2021.
43. Li X, Wang X, Zhao J, Wang J, Wu J. PRMT5 promotes colorectal cancer growth by interaction with MCM7. J Cell Mol Med. 2021;25:3537-3547.
44. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Canc. 2013;13:37-50.
45. Zheng BN, Ding CH, Chen SJ, Zhu K, Xie WF. Targeting PRMT5 activity inhibits the malignancy of hepatocellular carcinoma by promoting the transcription of HNF4a. Therapeutics. 2019;9:2606-2617.
46. Tae S, Karkhanis V, Velasco K, et al. Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res. 2011;39:5424-5438.
47. Hou Z, Peng H, Ayyanathan K, et al. The LIM protein AUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol Cell Biol. 2008;28:3198-3207.
48. Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA. PRMT5-mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington’s disease (HD). Cell Cycle. 2015;14:1716-1729.
49. Aggarwal P, Vaites LP, Kim JK, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. *Cancer Cell*. 2010;18:329-340.

50. Mavrakis KJ, McDonald ER, Schlabach MR, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. *Science*. 2016;351:1208-1213.

51. Jeon JY, Lee JS, Park ER, et al. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells. *Oncol Rep*. 2018;40:536-544.

52. Parkin DM. Global cancer statistics in the year 2000. *Lancet Oncol*. 2001;2:533-543.

53. Hamard PJ, Santiago GE, Liu F, et al. PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. *Cell Rep*. 2018;24:2643-2657.

54. Braun CJ, Stanciu M, Boutz PL, et al. Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma. *Cancer Cell*. 2017;32:411-426. e411.

55. Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. *Cell Mol Life Sci*. 2015;72:2041-2059.

56. Yuan Y, Nie H. Protein arginine methyltransferase 5: a potential cancer therapeutic target. *Cell Oncol*. 2021;44:33-44.

57. Chen H, Lorton B, Gupta V, Shechter D. A TGFβ/PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. *Oncogene*. 2017;36:373-386.

58. Fay MM, Clegg JM, Uchida KA, Powers MA, Ullman KS. Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability. *J Biol Chem*. 2014;289:17541-17552.

59. Pastore F, Bhagwat N, Pastore A, et al. PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2(V617F)-mutant MPN. *Cancer Discov*. 2020;10:1742-1757.

60. Jansson M, Durant ST, Cho EC, et al. Arginine methylation regulates the p53 response. *Nat Cell Biol*. 2008;10:1431-1439.